NEWAMSTERDAM PHARMA COMPANY N.V. WARRANT reports a Return on Equity (ROE) of -31.98%.

What is NAMSW's dividend yield?

NEWAMSTERDAM PHARMA COMPANY N.V. WARRANT offers a dividend yield of 0.00%.

What is NAMSW's Deepscope Quality Score?

Deepscope rates NAMSW's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy NAMSW?

Deepscope's AI Timing Score for NAMSW is 3 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

NAMSW (NASDAQ) 株価分析 | NEWAMSTERDAM PHARMA COMPANY N.V. WARRANT

Stock Check Daily update data at 9:30 AM
(Price: 2026-06-05 | FS: 2026-03-31)

NAMSW

NEWAMSTERDAM PHARMA COMPANY N.V. WARRANT

US:NASDAQ STOCK News 98

USD 19.72

-1.59 (-7.46%) Day Change

Watchlist Portfolio Compare Chart

0.00

D/E

-32.0%

ROE

-29.0%

ROA

0.00%

Div Yield

NEWAMSTERDAM PHARMA COMPANY N.V. WARRANT
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 19.72 Price -1.59 (-7.46%) Day Change	NEWS SCORE: 98

NAMSW, ファンダメンタルスコアはnot quite good ( ファンダメンタル = 54) そしてテクニカルスコアは ...(Sign In to See)...

Loading chart...

54 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROEが低い
ROAが低い
平均ROEが低い
ROAがROEに比べて低い
NPMが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...

Deepscope 分析

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	98
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	19.72
PBV / Sector	N/A / N/A
Earning Per Share	N/A

PE / Sector	N/A / N/A
PEG or PE/Growth / Sector	N/A / N/A
Average 1M Daily Value	0.04 M GREAT
Average 1W Daily Value	0.01 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

37%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

60%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-942.76 / N/A
NPM Average (%) / Sector	-731.31 / N/A
NPM Change Average (%) / Sector	1,403.68 / N/A
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-29.04 / N/A
ROA Average (%) / Sector	-27.84 / N/A
ROA Change Average (%) / Sector	234.22 / N/A GREAT
ROE (%) / Sector	-31.98 / N/A
ROE Average (%) / Sector	-32.06 / N/A
ROE Change Average (%) / Sector	254.62 / N/A GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / N/A
Dividend Average (%) / Sector	N/A / N/A
Dividend Change Average (%) / Sector	N/A / N/A

登録情報

Analyze Date	2026-06-06 09:09:04
Symbol	NAMSW
Name	NEWAMSTERDAM PHARMA COMPANY N.V. WARRANT
Sector
Market	NASDAQ
Listed Shares	0.00
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	N/A / N/A

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: Gooimeer 2-35, Naarden, Netherlands, 1411 DC

Phone: 31 35 206 2971

Website: https://www.newamsterdampharma.com

Employees: 100

Sector: -

Description: NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.